Acadia Healthcare Company, Inc. (ACHC) 股票分析

公司概述

Acadia Healthcare Company, Inc. specializes in delivering behavioral healthcare services across the United States and Puerto Rico, maintaining ownership and operational control of acute inpatient psychiatric facilities, specialty treatment centers, and residential recovery units. The company operates within the Healthcare sector, specifically under the Medical Care Facilities industry, positioning itself to address critical mental health needs through a network of specialized care institutions. Its scale is defined by a market capitalization of $2.51 billion, annual revenue reaching $3.31 billion, and an employee base of 19,000 individuals. These financial metrics indicate that Acadia Healthcare commands a significant position in the behavioral health landscape, generating substantial top-line revenue to fund its extensive facility network while employing a large workforce to deliver complex medical and therapeutic services.

财务健康

The company reported revenue of $3.31 billion over the trailing twelve months, yet recorded a net loss of $1,102,771,968, while generating positive EBITDA of $577.21 million. This substantial gap between positive EBITDA and negative net income reveals a cost structure heavily impacted by significant non-operating expenses, interest obligations, or taxes that erode bottom-line profitability despite underlying operational cash generation. Free cash flow stands at -$370,052,864, indicating that current operations are not generating sufficient cash to cover capital expenditures and working capital requirements, which constrains the company's immediate financial flexibility for strategic acquisitions or debt reduction. The gross margin is 41.5%, suggesting a moderate ability to control direct costs relative to revenue, while the operating margin of 5.8% reflects the high fixed cost environment typical of healthcare facilities where overhead expenses significantly compress operating profits. The profit margin is negative at -33.3%, confirming that the company is currently unprofitable on a net basis, which is a critical indicator of its current financial distress. On the balance sheet, cash holdings of $133.24 million are dwarfed by total debt of $2.65 billion, resulting in a debt-to-equity ratio of 124.03, which characterizes the capital structure as highly leveraged and sensitive to interest rate fluctuations. The current ratio of 1.55 suggests that the company possesses 1.55 dollars in current assets for every dollar of current liabilities, indicating a moderately healthy short-term liquidity position capable of meeting immediate obligations. Return on Equity is -41.0% and Return on Assets is 4.2%, where the negative ROE highlights the dilutive effect of losses on shareholder equity, while the positive ROA indicates that the company's assets are still generating some earnings before interest and taxes, though insufficient to offset financing costs.

估值评估

The trailing twelve-month P/E ratio is listed as N/A due to the net loss, whereas the forward P/E is 16.23, implying that the market prices the stock based on anticipated future earnings recovery rather than current profitability. The price-to-book ratio is 1.26, indicating that the market values the company at a slight premium of 26% above its net asset value, which may reflect expectations of future market share gains or brand value in the behavioral health sector. Alternative valuation metrics include a price-to-sales ratio of 0.76 and an EV/EBITDA of 9.05, suggesting that investors are valuing the firm primarily on its sales generation and operational cash flow potential rather than current earnings power. The stock has traded between a 52-week low of $11.43 and a 52-week high of $30.17, with the current price positioned significantly below the recent highs, reflecting ongoing market skepticism regarding the company's path to profitability. With a beta of 0.71, Acadia Healthcare exhibits lower volatility than the broader market, suggesting that its price movements are less sensitive to general market fluctuations compared to high-beta equities.

Growth & Income

Revenue growth year-over-year is 6.1%, demonstrating an expansion in top-line sales, while earnings growth is N/A due to the current net loss, indicating that revenue expansion has not yet translated into bottom-line improvement. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available earnings are theoretically retained, though in this context, the company is consuming cash reserves to service debt and fund operations. Consequently, the company reinvests its limited resources into maintaining facility networks and seeking operational efficiencies rather than distributing income to shareholders. The overall growth and income profile presents a trade-off where revenue expansion is positive but is currently offset by structural losses and negative free cash flow, requiring a successful turnaround in non-operating costs to achieve sustainable earnings growth and potential future dividend capability.